Feed RNAC
RN

Cartesian Therapeutics, Inc.

RNAC · NASDAQ

$8.19 -7.35% (-$0.65)
1M -6.08%
Market Cap $247.7M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/S 167.70x
P/FCF N/A
P/B N/A
Growth
0 /100
Declining
Rev. growth 70.66%
FCF growth N/A
Book val. growth N/A
Profitability
0 /100
Weak
FCF margin 5,291.54%
Op. margin 6,679.69%
Gross margin 766.42%
Quality
0 /100
Poor
ROA 48.31%
Asset turnover 0.00x
ROIC 30.78%
Debt
43 /100
Moderate
Int. coverage -188.07x
Current ratio 7.48x
Net debt/EBITDA N/A
Stability
26 /100
Unstable
Profitable years 0
EPS volatility 1,029.74%
Beta 0.62x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RNAC
Online

Sector

Healthcare

Industry

Biotechnology

CEO

Carsten Brunn

Employees

75

Headquarters

Frederick

Prihajajoči dogodki

05 NOV.

Earnings

Upcoming earnings report

54d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.